jefferies 2017 global healthcare conference · • infectious disease ... ngs sample prep market...
Post on 07-Jul-2020
0 Views
Preview:
TRANSCRIPT
1
Jefferies 2017 Global Healthcare ConferenceJune 2017
2
Some statements in this presentation may be forward-looking
statements, including, without limitation, statements regarding our
investment in high growth emerging markets and new products
and technologies, improvements to our operational efficiency and
our future financial performance. These statements are subject to
risks, uncertainties and other factors that could cause actual
results to differ materially from our expectations. Such factors
include, but are not limited to, recent changes to our global
organizational structure and executive management team,
difficulties in implementing our global ERP system, our ability to
develop and market new or improved products according to our
business plan, currency fluctuations and other factors discussed
in more detail in our recent filings with the SEC. We do not
undertake any obligation to publicly update any forward-looking
statements.
Forward-Looking Statements
3
• Continuous innovation
• Sales exceed $2 Billion
• Over 60 years of strong performance
• Apply key competencies to fuel growth
• More than 8,000 employees worldwide
• Complementary business mix
Bio-Rad Profile
A leading global provider of sophisticated products
to the life science research and diagnostic markets
4
• A leader in Life Science and Clinical Diagnostics
• Direct focus on the customer
• Invest in high growth emerging markets
• Improve operational efficiency and cash flow
Bio-Rad Strategy
Key Components
5
Leading Market Positions
Over 80% of sales are from products in which
Bio-Rad has a leading position in the market
DigitalBiology
Diagnostics• Autoimmune testing
• Diabetes Monitoring
• HIV testing
• Immuno-hematology
• Quality Controls
Life Science• Bio-chromatography
• DNA Amplification
• Electrophoresis
• Gel Image Analysis
• Protein Assays
6
Customer Focus
Biopharmaceutical
9%
Reference Labs
15%
Transfusion Labs
15%
Academic
23%
Industrial
3%Hospital Labs
35%
Diversified Customer Base
Recurring Revenues
Broad Product Base
Worldwide Presence
Americas
43%
Europe / Africa
38%Asia / Pacific
19%
7
Circle of Discovery -
Life Science Research Products
Gene Transfer and Modulation
Reagents expansion
Protein FunctionIdentification and interaction
ElectrophoresisOpportunities to gain market share
and leverage new technologies
Protein ExpressionMulti-analyte detection
Chromatography
Cellular AnalysisImaging and Cell Sorting
Food SafetyGrowth in food pathogen
testing
Digital BiologyDroplet Digital PCR
Image AnalysisGrowth markets in software and
digital microscopy
AmplificationPCR, qPCR
Gene Transfer and Modulation
Reagents expansion
Protein FunctionIdentification and interaction
ElectrophoresisOpportunities to gain market share
and leverage new technologies
ElectrophoresisOpportunities to gain market share
and leverage new technologies
Protein ExpressionMulti-analyte detection
Protein ExpressionMulti-analyte detection
ChromatographyChromatography
Cellular AnalysisImaging and Cell Sorting
Cellular AnalysisImaging and Cell Sorting
Food SafetyGrowth in food pathogen
testing
Food SafetyGrowth in food pathogen
testing
Digital BiologyDroplet Digital PCR
Digital BiologyDroplet Digital PCR
Image AnalysisGrowth markets in software and
digital microscopy
Image AnalysisGrowth markets in software and
digital microscopy
AmplificationPCR, qPCR
AmplificationPCR, qPCR
8
Clinical Diagnostics Products
Integrated Systems Approach
Quality Controls
Diagnostic Tests
Specialized
Testing
Instruments
• Quality controls
• Infectious disease
• AIDS/HIV
• Blood Virus detection
• Microbiology
• Diabetes monitoring
• Genetic disease screening
• Autoimmune testing
• Blood typing
9
Investing in High Growth Emerging Markets
Emerging Geographies
10
Investing in the Future
Technologies
ddPCR
GlobalizationSystems
New Markets
Cell Biology
Global Operating ModelGlobal ERP System
11
Investing in Cell Biology
Antibodies
Cell Visualization
Cell Counting
Flow Cytometry
Cell Sorter
12
Investing in Droplet Digital PCR
Droplet Digital System
Automated Droplet Generator
Reagents, Assays and
Consumables
13
Application of ddPCR
The Olivia Newton-John Cancer Research Institute
has become the first laboratory in Australia to be NATA
accredited for a breakthrough technology to perform
blood tests for melanoma patients to detect and analyse
cancer genes. This new approach is already saving lives.
Melanoma Liquid Biopsy
14
Building on a Key Franchise – RainDance Technologies
• Expands intellectual property portfolio
• Leverage technology to grow position in
NGS sample prep market
• Enables accelerated new product
development
RainDance Acquisition
RainDrop Plus
System
ThunderBolts Cancer and
Myeloid Panels
15
Illumina Bio-Rad Partnership
End-to-end single-cell sequencing solution
NextSeq™, BaseSpace™,
and SeqGeq™
SureCell™ WTA 3’
Library Prep KitsddSEQ™
Single-Cell Isolator
• Sensitive and unbiased characterization of transcriptional
signatures
• Scalable solution to accommodate a wide range of
experimental designs
16
Investing in the U.S. Immunohematology Market
We now have a complete portfolio of solutions
in the US with recent FDA approval
IH-1000
Tango infinity
Manual Reagents
Connectivity with IH-Com / IH-Web
Gel Card
Technology
IH-1000
17
Investing in our Future
Improve Operational Efficiency
Global ERP System
Operating Efficiency
Standardized Process
18
Investing in Globalization
Opportunities to Optimize Operations
Global Procurement
Global Manufacturing
Global Logistics
Shared Services
Global Commercial Organization
19
2017 Outlook
• Opportunity for Sales Growth
Good momentum for new products
Research funding holding steady
Expansion into U.S. Blood Typing market
Increased price pressure and competition for Diagnostics
• Significant Internal Investments
New product areas such as droplet digital PCR, cell biology, and
diagnostic sequencing
Global ERP and IT systems
Organization and operating model improvements
2017 Outlook
Organic Sales Growth ~ 4.0%
Gross Margin ~ 55.0%
Operating Margin ~ 7.0% Currency neutral
20
Driving Future Opportunity
• Top line growth
• Completing operating investments
• Driving efficiencies
• Expanding margins
Focus for 2017 - 2018
21
Thank you!
top related